Truist Initiates Buy Rating on Altimmune, Highlights Pemvidutide's Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy ALT?
Source: seekingalpha
- Therapeutic Potential: Truist has initiated coverage of Altimmune (ALT) with a buy rating, suggesting that its lead candidate pemvidutide could become a significant treatment for metabolic dysfunction-associated steatohepatitis (MASH), indicating strong market prospects.
- Price Target: The analyst set a price target of $12, which implies approximately 251% upside based on the March 18 close, reflecting optimistic market expectations for the drug's performance.
- Clinical Trial Results: The 48-week phase 2 MOMENTUM trial released in late 2023 showed an average weight loss of 15.6% at the highest tested dose of 2.4 mg, demonstrating its efficacy in obesity treatment.
- Multiple Indications: In addition to MASH, pemvidutide is also undergoing phase 2 trials for alcohol use disorder and alcohol-associated liver disease, further expanding its clinical application and enhancing Altimmune's competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.020
Low
12.00
Averages
16.00
High
20.00
Current: 3.020
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
Stock Price Target: The average 12-month price target for Altimmune (ALT) is $18, indicating a potential upside of 495% from its current trading level of $3.02.
Upcoming Trials: Altimmune is preparing to initiate a late-stage trial of pemvidutide for treating metabolic dysfunction-associated steatotic liver disease (MASLD) in 2026, with expectations to evaluate multiple doses over a 52-week treatment period.
Analyst Ratings: Among analysts covering Altimmune, nine have a 'Buy' or higher rating, while one has a 'Hold' and another a 'Sell' rating, reflecting a generally positive outlook despite recent stock performance.
Retail Sentiment: Retail sentiment around Altimmune's stock has shifted from 'bearish' to 'neutral' in the past 24 hours, although overall messaging volume remains low, indicating mixed investor confidence.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Truist Initiates Buy Rating on Altimmune, Highlights Pemvidutide's Potential
- Therapeutic Potential: Truist has initiated coverage of Altimmune (ALT) with a buy rating, suggesting that its lead candidate pemvidutide could become a significant treatment for metabolic dysfunction-associated steatohepatitis (MASH), indicating strong market prospects.
- Price Target: The analyst set a price target of $12, which implies approximately 251% upside based on the March 18 close, reflecting optimistic market expectations for the drug's performance.
- Clinical Trial Results: The 48-week phase 2 MOMENTUM trial released in late 2023 showed an average weight loss of 15.6% at the highest tested dose of 2.4 mg, demonstrating its efficacy in obesity treatment.
- Multiple Indications: In addition to MASH, pemvidutide is also undergoing phase 2 trials for alcohol use disorder and alcohol-associated liver disease, further expanding its clinical application and enhancing Altimmune's competitive position in the market.
See More
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
- Clinical Trial Progress: Altimmune plans to initiate a global Phase III MASH trial in 2026, enrolling approximately 1,800 patients to primarily assess the efficacy of pemvidutide at 1.8 mg and 2.4 mg doses, aiming to address significant unmet needs in liver disease.
- Improved Financial Position: As of year-end 2025, Altimmune reported total cash of $274 million, with a pro forma cash position expected to extend into 2028 following January's fundraising, thereby supporting the advancement of clinical programs.
- R&D Expense Changes: R&D expenses for Q4 2025 were $18.4 million, a decrease from $19.8 million in the same period of 2024, indicating a strategic adjustment in resource allocation by the company.
- Positive Market Response: Market research indicated that over 70% of physicians expressed a high likelihood of prescribing pemvidutide, with projected usage rates of 43% and 51% among F2 and F3 patients, respectively, suggesting strong potential acceptance and competitiveness in the market.
See More
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
Stock Price Target: The average 12-month price target for Altimmune (ALT) is $18, indicating a potential upside of 495% from its current trading level of $3.02.
Upcoming Trials: Altimmune is preparing to initiate a late-stage trial of pemvidutide for treating metabolic dysfunction-associated steatotic liver disease (MASLD) in 2026, with expectations to evaluate multiple doses over a 52-week treatment period.
Analyst Ratings: Among analysts covering Altimmune, nine have a 'Buy' or higher rating, while one has a 'Hold' and another a 'Sell' rating, reflecting a generally positive outlook despite recent stock performance.
Retail Sentiment: Retail sentiment around Altimmune's stock has shifted from 'bearish' to 'neutral' in the past 24 hours, although overall messaging volume remains low, indicating mixed investor confidence.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Truist Initiates Buy Rating on Altimmune, Highlights Pemvidutide's Potential
- Therapeutic Potential: Truist has initiated coverage of Altimmune (ALT) with a buy rating, suggesting that its lead candidate pemvidutide could become a significant treatment for metabolic dysfunction-associated steatohepatitis (MASH), indicating strong market prospects.
- Price Target: The analyst set a price target of $12, which implies approximately 251% upside based on the March 18 close, reflecting optimistic market expectations for the drug's performance.
- Clinical Trial Results: The 48-week phase 2 MOMENTUM trial released in late 2023 showed an average weight loss of 15.6% at the highest tested dose of 2.4 mg, demonstrating its efficacy in obesity treatment.
- Multiple Indications: In addition to MASH, pemvidutide is also undergoing phase 2 trials for alcohol use disorder and alcohol-associated liver disease, further expanding its clinical application and enhancing Altimmune's competitive position in the market.
See More
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
- Clinical Trial Progress: Altimmune plans to initiate a global Phase III MASH trial in 2026, enrolling approximately 1,800 patients to primarily assess the efficacy of pemvidutide at 1.8 mg and 2.4 mg doses, aiming to address significant unmet needs in liver disease.
- Improved Financial Position: As of year-end 2025, Altimmune reported total cash of $274 million, with a pro forma cash position expected to extend into 2028 following January's fundraising, thereby supporting the advancement of clinical programs.
- R&D Expense Changes: R&D expenses for Q4 2025 were $18.4 million, a decrease from $19.8 million in the same period of 2024, indicating a strategic adjustment in resource allocation by the company.
- Positive Market Response: Market research indicated that over 70% of physicians expressed a high likelihood of prescribing pemvidutide, with projected usage rates of 43% and 51% among F2 and F3 patients, respectively, suggesting strong potential acceptance and competitiveness in the market.
See More
